The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorChulalongkorn University
About this trial
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Eligibility criteria
Qualifiers
Age 18 years or more
Hospitalized for the primary diagnosis of acute denovo or decompensated chronic heart regardless of ejection fraction
AKI KDIGO any stage or urine NGAL ≥ 150 ng/mL
Must be able to be enrolled into the trial ≤ 12 hours of diagnosis of AKI or elevated urine NGAL
Disqualifiers
Denied to participate in the study
Cardiogenic shock or unstable hemodynamic (systolic blood pressure of at least 100 mmHg or required inotropic support within last 24 hours)
Cardiac mechanical support (i.e. extracorporeal membrane oxygenation and intra-aortic balloon pump)
Acute coronary syndrome
Trial design
Treatments tested in this trial
- Empagliflozin 10 MG
- Placebo
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov